AbbVie announced that the FDA has granted Breakthrough Therapy Designations (BTDs) for its investigational drug Temab-A (telisotuzumab adizutecan) in treating colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Temab-A, a next-generation antibody-drug conjugate targeting the c-Met protein, showed promising results in early studies, addressing treatment-resistant cancers. These designations aim to expedite Temab-A's development and review, highlighting its potential as a new therapy for difficult-to-treat solid tumors. AbbVie is continuing clinical trials to evaluate Temab-A both as a monotherapy and in combination with other treatments.
AbbVie shares are trading at USD 268.18 on Pluang as of Oct 07, 2026 19:44 WIB, up 0.52% in the last day. The stock shows strong buying interest with 81% of orders to buy. AbbVie’s market cap stands at $471.27 billion, reflecting its significant presence in the health sector.
AbbVie's stock performance shows that investors who bought shares during periods of market pessimism, such as after the Allergan selloff in 2019, earned higher returns than those who bought on positive drug approval news. For example, buying AbbVie a...
The Phase 3 EPCORE DLBCL-2 trial showed that adding epcoritamab, a bispecific antibody, to standard R-CHOP therapy significantly improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients with intermediate to...
